Adult leukemia patients get Kid-Style chemo combo in new trial

NCT ID NCT01920737

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing whether a combination of chemotherapy drugs typically used in children can be safe and effective for adults aged 18 to 60 with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). The study aims to see if this 'pediatric-inspired' regimen helps achieve deep remission with fewer side effects. Thirty-nine participants are receiving a multi-drug regimen over several phases, with close monitoring for response and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: combination chemotherapy (daunorubicin, vincristine, prednisone, PEG-asparaginase, methotrexate, 6-mercaptopurine, cyclophosphamide, cytarabine, leucovorin, dexamethasone)
What this could lead to: If successful, this could offer a more effective and safer chemotherapy regimen for adults with Ph-negative ALL, potentially improving remission rates.
What could go wrong: This is a small, early-phase (phase 2) study with only 39 participants. The regimen may not work as well in adults as in children, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOBLASTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia leukemia lymphoblastic lymphoma T-lymphoblastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA

Contacts and locations

Locations

Duke University Medical Center

Durham, North Carolina, 27701, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Weill Cornell Medical Center

New York, New York, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.